Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Graf

Showing results (31-40 of 102) with videos related to

Pageof 11
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 2, 2008
Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effectsChrista Claes, Ralf René Reinert, Johann-Matthias Graf von der Schulenburg
Journal of the American Chemical Society|December 28, 2020
Suppression of Hydrogen Evolution in Acidic Electrolytes by Electrochemical CO<sub>2</sub> ReductionChristoph J Bondue, Matthias Graf, Akansha Goyal, et al.
Journal of Clinical Medicine|April 12, 2022
Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)Myron Zaczkiewicz, Katharina Kostenzer, Matthias Graf, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 12, 2017
[Priority setting and rationing of pharmaceuticals - an experimental analysis of discussion processes]Ines Aumann, Svenja Litzkendorf, Kathrin Damm, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 22, 2007
Methods for determining cost-benefit ratios for pharmaceuticals in GermanyJ- Matthias Graf von der Schulenburg, Christoph Vauth, Thomas Mittendorf, et al.
Health Policy (Amsterdam, Netherlands)|March 7, 2002
Diffusion of innovations: treatment of Alzheimer's disease in GermanyJörg Ruof, Thomas Mittendorf, Olaf Pirk, et al.
Mediators of Inflammation|May 7, 2014
C-reactive protein in human atherogenesis: facts and fictionOliver Zimmermann, Kefei Li, Myron Zaczkiewicz, et al.
Public Health Genomics|June 23, 2017
Health-Related Genetic Direct-to-Consumer Tests in the German Setting: The Available Offer and the Potential Implications for a Solidarily Financed Health-Care SystemMarika Plöthner, Mike Klora, Daniel Rudolph, et al.
Herz|January 22, 2009
[Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases]Jan Zeidler, Thomas Mittendorf, Gunda Vahldiek, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 24, 2009
[Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]Christa Claes, Thomas Mittendorf, Martin Grond, et al.
Pageof 11

Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 2, 2008
Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effectsChrista Claes, Ralf René Reinert, Johann-Matthias Graf von der Schulenburg
Journal of the American Chemical Society|December 28, 2020
Suppression of Hydrogen Evolution in Acidic Electrolytes by Electrochemical CO<sub>2</sub> ReductionChristoph J Bondue, Matthias Graf, Akansha Goyal, et al.
Journal of Clinical Medicine|April 12, 2022
Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)Myron Zaczkiewicz, Katharina Kostenzer, Matthias Graf, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 12, 2017
[Priority setting and rationing of pharmaceuticals - an experimental analysis of discussion processes]Ines Aumann, Svenja Litzkendorf, Kathrin Damm, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 22, 2007
Methods for determining cost-benefit ratios for pharmaceuticals in GermanyJ- Matthias Graf von der Schulenburg, Christoph Vauth, Thomas Mittendorf, et al.
Health Policy (Amsterdam, Netherlands)|March 7, 2002
Diffusion of innovations: treatment of Alzheimer's disease in GermanyJörg Ruof, Thomas Mittendorf, Olaf Pirk, et al.
Mediators of Inflammation|May 7, 2014
C-reactive protein in human atherogenesis: facts and fictionOliver Zimmermann, Kefei Li, Myron Zaczkiewicz, et al.
Public Health Genomics|June 23, 2017
Health-Related Genetic Direct-to-Consumer Tests in the German Setting: The Available Offer and the Potential Implications for a Solidarily Financed Health-Care SystemMarika Plöthner, Mike Klora, Daniel Rudolph, et al.
Herz|January 22, 2009
[Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases]Jan Zeidler, Thomas Mittendorf, Gunda Vahldiek, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 24, 2009
[Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]Christa Claes, Thomas Mittendorf, Martin Grond, et al.
Pageof 11